Phase II Chemoimmunotherapy Combining Nivolumab with Standard Chemo in Newly Diagnosed NPC

The National Cancer Institute is evaluating the addition of nivolumab to gemcitabine and cisplatin chemotherapy, followed by radiation, for patients with stage II–IV nasopharyngeal carcinoma. This innovative trial aims to assess both efficacy and tolerability, with a special focus on reducing radiation doses—and therefore side effects—in pediatric patients.